Phase Ib/II, multicentre, open-label, randomized, clinical study with dose optimization of two different schedules of Elisidepsin Trifluoroacetate (Irvalec) as a single agent in patients with unresectable, locally advanced or metastatic Esophageal, Esophagogastric Junction or Gastric Cancer after failure of one but not more than two prior lines of systemic therapy.

Trial Profile

Phase Ib/II, multicentre, open-label, randomized, clinical study with dose optimization of two different schedules of Elisidepsin Trifluoroacetate (Irvalec) as a single agent in patients with unresectable, locally advanced or metastatic Esophageal, Esophagogastric Junction or Gastric Cancer after failure of one but not more than two prior lines of systemic therapy.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Elisidepsin (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms IMAGE
  • Most Recent Events

    • 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.
    • 23 Jun 2012 Planned number of patients changed from 118 to 126 as reported by European Clinical Trials Database.
    • 11 Apr 2012 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top